PL2291523T3 - Czynnik VIII, czynnik von Willebranda lub ich kompleksy o wydłużonym okresie półtrwania in vivo - Google Patents

Czynnik VIII, czynnik von Willebranda lub ich kompleksy o wydłużonym okresie półtrwania in vivo

Info

Publication number
PL2291523T3
PL2291523T3 PL09768986T PL09768986T PL2291523T3 PL 2291523 T3 PL2291523 T3 PL 2291523T3 PL 09768986 T PL09768986 T PL 09768986T PL 09768986 T PL09768986 T PL 09768986T PL 2291523 T3 PL2291523 T3 PL 2291523T3
Authority
PL
Poland
Prior art keywords
complexes
prolonged
factor
life
von willebrand
Prior art date
Application number
PL09768986T
Other languages
English (en)
Inventor
Thomas Weimer
Stefan Schulte
Hubert Metzner
Ulrich Kronthaler
Holger Lind
Wiegand Lang
Original Assignee
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Gmbh filed Critical Csl Behring Gmbh
Publication of PL2291523T3 publication Critical patent/PL2291523T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL09768986T 2008-06-24 2009-06-24 Czynnik VIII, czynnik von Willebranda lub ich kompleksy o wydłużonym okresie półtrwania in vivo PL2291523T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08011429 2008-06-24
PCT/EP2009/004549 WO2009156137A1 (en) 2008-06-24 2009-06-24 Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
EP09768986.3A EP2291523B1 (en) 2008-06-24 2009-06-24 Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life

Publications (1)

Publication Number Publication Date
PL2291523T3 true PL2291523T3 (pl) 2015-05-29

Family

ID=40042814

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09768986T PL2291523T3 (pl) 2008-06-24 2009-06-24 Czynnik VIII, czynnik von Willebranda lub ich kompleksy o wydłużonym okresie półtrwania in vivo

Country Status (12)

Country Link
US (2) US8575104B2 (pl)
EP (2) EP2865760B1 (pl)
JP (1) JP5832285B2 (pl)
KR (2) KR101648734B1 (pl)
CN (2) CN103739712B (pl)
AU (1) AU2009262476C1 (pl)
CA (1) CA2728012C (pl)
DK (2) DK2865760T3 (pl)
ES (2) ES2654336T3 (pl)
PL (1) PL2291523T3 (pl)
RU (1) RU2528855C2 (pl)
WO (1) WO2009156137A1 (pl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6263355A (ja) * 1985-09-13 1987-03-20 Hitachi Ltd バツテリバツクアツプｒａｍのチエツク方法
DK2865760T3 (en) 2008-06-24 2018-01-15 Csl Behring Gmbh Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
CN102741275B (zh) 2009-08-24 2016-08-03 阿穆尼克斯运营公司 凝血因子ix组合物及其制备和使用方法
KR101808751B1 (ko) 2009-11-13 2017-12-13 그리폴스 테라퓨틱스 인코포레이티드 폰 빌레브란트 인자(ｖＷＦ)-함유 제제, 및 그와 관련된 방법, 키트 및 용도
JP5914363B2 (ja) * 2010-02-16 2016-05-11 ノヴォ ノルディスク アー／エス 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子
US9493543B2 (en) 2010-02-16 2016-11-15 Novo Nordisk A/S Factor VIII fusion protein
WO2011101277A1 (en) 2010-02-16 2011-08-25 Novo Nordisk A/S Conjugated proteins
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
KR101969515B1 (ko) * 2011-06-10 2019-04-16 박스알타 인코퍼레이티드 재조합 vwf의 투여에 의한 응고 질환의 치료
EP2804623B1 (en) * 2012-01-12 2019-08-07 Bioverativ Therapeutics Inc. Chimeric factor viii polypeptides and uses thereof
HK1205188A1 (en) * 2012-02-14 2015-12-11 Portola Pharmaceuticals, Inc. Process for making recombinant antidote to factor xa inhibitor
LT3564260T (lt) 2012-02-15 2023-01-10 Bioverativ Therapeutics Inc. Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai
WO2013120939A1 (en) 2012-02-15 2013-08-22 Csl Behring Gmbh Von willebrand factor variants having improved factor viii binding affinity
EP2822577B1 (en) * 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
WO2013083858A1 (en) 2012-04-24 2013-06-13 Novo Nordisk A/S Compounds suitable for treatment of haemophilia
CN110054699A (zh) * 2012-07-11 2019-07-26 比奥贝拉蒂治疗公司 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
US10231993B2 (en) 2013-06-27 2019-03-19 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
EP3013359A4 (en) * 2013-06-28 2017-01-25 Biogen MA Inc. Thrombin cleavable linker
MX2015016567A (es) * 2013-06-28 2016-03-31 Biogen Ma Inc Enlazador escindible por trombina con xten y usos del mismo.
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
US10246485B2 (en) 2013-11-08 2019-04-02 Csl Limited Method to concentrate von willebrand factor or complexes thereof
SG11201605242YA (en) * 2014-01-10 2016-07-28 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
CN106414719B (zh) 2014-06-13 2020-02-14 杰特有限公司 生物反应器中重组von Willebrand因子的改进生产
DE102014011653A1 (de) * 2014-06-20 2015-12-24 Ulrich Loos Nachweis von Autoantikörpern gegen den TSH-Rezeptor
BR112016030950A2 (pt) 2014-07-02 2018-03-27 Csl Ltd polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira.
US10626164B2 (en) 2014-07-25 2020-04-21 Csl Limited Purification of VWF
WO2016127057A1 (en) * 2015-02-06 2016-08-11 The University Of North Carolina At Chapel Hill Optimized human clotting factor viii gene expression cassettes and their use
CA2978374A1 (en) 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
US10772936B2 (en) 2015-05-22 2020-09-15 CSL Behring Lengnau AG Methods for preparing modified von Willebrand factor
SG10201910896UA (en) 2015-05-22 2020-01-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
WO2017112895A1 (en) * 2015-12-23 2017-06-29 Haplomics, Inc. F8 gene repair
MX2018008337A (es) * 2016-01-07 2018-09-17 CSL Behring Lengnau AG Factor de von willebrand truncado mutado.
AU2017205776B2 (en) * 2016-01-07 2020-09-10 CSL Behring Lengnau AG Mutated von Willebrand factor
DK3458085T5 (da) * 2016-05-20 2024-09-09 Octapharma Ag Glykosyleret vwf-fusionsproteiner med forbedret farmakokinetik
JP6877469B2 (ja) * 2016-06-24 2021-05-26 モガム・インスティテュート・フォー・バイオメディカル・リサーチＭｏｇａｍ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ Ｆｖｉｉｉおよびｖｗｆ因子を含むキメラタンパク質、ならびにそれらの使用
TW201828974A (zh) 2016-11-11 2018-08-16 瑞士商Ｃｓｌ貝林重組技能公司 用於血管外施予以治療或預防凝血疾病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類
KR20190085021A (ko) 2016-11-11 2019-07-17 체에스엘 베링 렝나우 아게 혈우병을 치료하기 위한 절단된 폰 빌레브란트 인자 폴리펩타이드
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
US11141466B2 (en) 2017-06-22 2021-10-12 CSL Behring Lengnau AG Modulation of FVIII immunogenicity by truncated VWF
DK3648788T3 (da) 2017-07-07 2024-08-19 Takeda Pharmaceuticals Co Behandling af gastrointestinal blødning hos patienter med svær von willebrand-sygdom ved administration af rekombinant vwf
PT3648787T (pt) * 2017-07-07 2025-01-20 Takeda Pharmaceuticals Co Tratamento de doentes com doença de von willebrand grave submetidos a cirurgia eletiva por administração de vwf recombinante
BR112020002234A2 (pt) * 2017-08-23 2020-07-28 Csl Behring Gmbh método para a filtragem de virus do fator von willebrand
SI3793588T1 (sl) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Postopki zdravljenja hemofilije A
JP2022514954A (ja) * 2018-12-23 2022-02-16 シーエスエル・ベーリング・エルエルシー キルスイッチを有するドナーｔ細胞
BR112021015068A2 (pt) 2019-02-01 2021-10-05 Takeda Pharmaceutical Company Limited Métodos de tratamento profilático usando vwf recombinante (rvwf)
CN111592591B (zh) * 2020-06-17 2021-12-14 博雅生物制药集团股份有限公司 一种人血管性血友病因子/人凝血因子ⅷ复合物的制备方法及产物和应用
CN117720671B (zh) * 2024-01-30 2024-06-14 南通大学 具有自组装性能的重复结构单元重组蛋白ⅠAⅠB-ⅠAⅠBrQTY及应用
CN121319224B (zh) * 2025-12-18 2026-04-28 山东艾科达生物科技有限公司 一种检测adamts13活性的蛋白组合及其应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
FR2673632A1 (fr) * 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
EP1621206A1 (en) 1994-12-12 2006-02-01 Beth Israel Deaconess Medical Center, Inc. Chimeric cytokines and uses thereof
AU6455896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
CA2252896C (en) 1996-04-24 2009-03-10 The Regents Of The University Of Michigan Inactivation resistant factor viii
US20040092442A1 (en) 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
US6103077A (en) * 1998-01-02 2000-08-15 De Nora S.P.A. Structures and methods of manufacture for gas diffusion electrodes and electrode components
CA2329768C (en) 1998-04-27 2008-06-10 Opperbas Holding B.V. Pharmaceutical composition comprising factor viii and neutral liposomes
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1274720A4 (en) * 2000-04-12 2004-08-18 Human Genome Sciences Inc FUSION PROTEINS CONTAINING ALBUMIN
EP1148063A1 (de) 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
EP1351986A2 (en) 2001-01-12 2003-10-15 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
EP2110385A1 (en) 2001-06-14 2009-10-21 The Scripps Research Institute Stabilized factor VIII with engineered disulfide bonds
WO2003076567A2 (en) 2002-03-05 2003-09-18 Eli Lilly And Company Heterologous g-csf fusion proteins
WO2003093313A2 (en) 2002-04-29 2003-11-13 Baxter International Inc. Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein
KR20140148502A (ko) * 2002-12-09 2014-12-31 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
EP1444986A1 (en) * 2003-02-07 2004-08-11 Aventis Behring GmbH Pharmaceutical preparation for the improved treatment of blood-clotting disorders
WO2004075923A2 (en) 2003-02-26 2004-09-10 Nektar Therapeutics Al, Corporation Polymer-factor viii moiety conjugates
ES2333598T5 (es) * 2003-05-06 2013-09-04 Biogen Idec Hemophilia Inc Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia.
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
JP4629047B2 (ja) 2003-06-12 2011-02-09 イーライ リリー アンド カンパニー Ｇｌｐ−１アナログ複合タンパク質
EP1502921A1 (en) 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
US7550263B2 (en) 2003-09-05 2009-06-23 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
BRPI0417916A (pt) 2003-12-31 2007-04-10 Merck Patent Gmbh proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
KR101468345B1 (ko) 2004-11-12 2014-12-03 바이엘 헬스케어 엘엘씨 Ｆｖｉｉｉ의 부위 지향 변형
BRPI0519562A2 (pt) * 2004-12-27 2009-01-27 Baxter Int construÇço proteinÁcea, complexo, mÉtodo para prolongar a meia-vida in vivo de fator viii (fviii) ou um derivado biologicamente ativo do mesmo composiÇço farmacÊutica, e, mÉtodo para formar uma construÇço proteinÁcea
KR20080007226A (ko) 2005-04-14 2008-01-17 체에스엘 베링 게엠베하 증가된 안정성을 가진 변형된 응고 인자 ⅷ 및 이의 유도체
CA2627478A1 (en) 2005-10-28 2007-05-03 Dnavec Corporation Therapeutic method for blood coagulation disorder
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
KR20080108147A (ko) 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 페질화된 인자 ｖｉｉｉ
DK3896090T3 (da) 2006-06-14 2022-03-21 Csl Behring Gmbh Proteolytisk spalteligt fusionsprotein omfattende en blodkoagutionsfaktor
EP1867660A1 (en) * 2006-06-14 2007-12-19 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
DK2865760T3 (en) 2008-06-24 2018-01-15 Csl Behring Gmbh Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life
US9402754B2 (en) * 2010-05-18 2016-08-02 Abbott Cardiovascular Systems, Inc. Expandable endoprostheses, systems, and methods for treating a bifurcated lumen
EP2804623B1 (en) 2012-01-12 2019-08-07 Bioverativ Therapeutics Inc. Chimeric factor viii polypeptides and uses thereof
WO2013083858A1 (en) 2012-04-24 2013-06-13 Novo Nordisk A/S Compounds suitable for treatment of haemophilia

Also Published As

Publication number Publication date
KR101507718B1 (ko) 2015-04-10
CN102076855A (zh) 2011-05-25
DK2291523T3 (en) 2015-03-23
KR20110044978A (ko) 2011-05-03
CA2728012A1 (en) 2009-12-30
US9290561B2 (en) 2016-03-22
WO2009156137A1 (en) 2009-12-30
EP2291523B1 (en) 2014-12-17
AU2009262476A1 (en) 2009-12-30
EP2865760A1 (en) 2015-04-29
EP2291523A1 (en) 2011-03-09
US20110183907A1 (en) 2011-07-28
ES2531464T3 (es) 2015-03-16
RU2528855C2 (ru) 2014-09-20
CN103739712A (zh) 2014-04-23
KR20140090703A (ko) 2014-07-17
RU2011102366A (ru) 2012-07-27
HK1151068A1 (en) 2012-01-20
KR101648734B1 (ko) 2016-08-18
ES2654336T3 (es) 2018-02-13
CA2728012C (en) 2017-10-31
EP2865760B1 (en) 2017-10-11
DK2865760T3 (en) 2018-01-15
JP5832285B2 (ja) 2015-12-16
US8575104B2 (en) 2013-11-05
AU2009262476C1 (en) 2016-06-02
CN103739712B (zh) 2016-10-05
AU2009262476B2 (en) 2014-06-26
US20140072561A1 (en) 2014-03-13
JP2011525363A (ja) 2011-09-22

Similar Documents

Publication Publication Date Title
AP3856A (en) Improvements in feedwells.
IL212941A0 (en) Usirna complexes
PL2257493T3 (pl) Ramię załadowcze z bezpośrednią regulacją, w szczególności regulacją proporcjonalną
IL216014A0 (en) Antibodies immunorective with heregulin-her3 complexes, compositions comprising the same and uses thereof
EP2332328A4 (en) PROVIDING ADDITIONAL INFORMATION
AP2011005690A0 (en) Combination therapy with peptide epoxyketones.
IL206765A0 (en) 4,5-dihydro-oxazol-2-yl-amine derivatives
ZA201101923B (en) Dual character polymer useful in fabric care products
PL2203439T3 (pl) 1',3'-dipodstawione-4-fenylo-3,4,5,6-tetrahydro-2H, 1'H-[1, 4']bipirydynylo-2'-ketony
PL1984503T5 (pl) Zmodyfikowany czynnik krzepnięcia viia o wydłużonym okresie półtrwania
TWI370040B (en) Simultanes doppelseitenschleifen von halbleiterscheiben
ZA201007559B (en) Factor ix conjugates with extended half-lives
EP1839508A4 (en) CLOTHES WITH LINING OF THE GLOVE TYPE
GB0801411D0 (en) Improvements in bondwire design
SI2356123T1 (sl) Piro-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo(e)azuleni
EP2365820A4 (en) ENDOTHEL SIMULATING NANOMATRIX
TWI371781B (en) Quantum well intermixing
PL2358468T3 (pl) Ulepszenia dotyczące katalizatorów
GB0705076D0 (en) The Pump
EP1896492A4 (en) PLATINUM COMPLEXES WITH MONONITRYLIC LIGANDS
Westerhoff Set in our Ways
GB0817436D0 (en) The new scaffolder's level
GB0801912D0 (en) Bifunctional proteinaceous complexes
田辺元 01. Onthologie von Dr. Heidegger.
PH32005000478S1 (en) Wire collapsible with trolley